CN115715189B - Kcnt1抑制剂和使用方法 - Google Patents

Kcnt1抑制剂和使用方法

Info

Publication number
CN115715189B
CN115715189B CN202180035479.0A CN202180035479A CN115715189B CN 115715189 B CN115715189 B CN 115715189B CN 202180035479 A CN202180035479 A CN 202180035479A CN 115715189 B CN115715189 B CN 115715189B
Authority
CN
China
Prior art keywords
mmol
compound
trifluoromethyl
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180035479.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115715189A (zh
Inventor
G·马丁内斯·博泰拉
A·M·格里芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Pharmaceuticals
Original Assignee
Praxis Precision Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Pharmaceuticals filed Critical Praxis Precision Pharmaceuticals
Priority to CN202610125645.0A priority Critical patent/CN121868303A/zh
Publication of CN115715189A publication Critical patent/CN115715189A/zh
Application granted granted Critical
Publication of CN115715189B publication Critical patent/CN115715189B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180035479.0A 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法 Active CN115715189B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610125645.0A CN121868303A (zh) 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993359P 2020-03-23 2020-03-23
US62/993,359 2020-03-23
PCT/US2021/023653 WO2021195066A2 (en) 2020-03-23 2021-03-23 Kcnt1 inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610125645.0A Division CN121868303A (zh) 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法

Publications (2)

Publication Number Publication Date
CN115715189A CN115715189A (zh) 2023-02-24
CN115715189B true CN115715189B (zh) 2026-02-13

Family

ID=77892612

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180035479.0A Active CN115715189B (zh) 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法
CN202610125645.0A Pending CN121868303A (zh) 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610125645.0A Pending CN121868303A (zh) 2020-03-23 2021-03-23 Kcnt1抑制剂和使用方法

Country Status (11)

Country Link
US (1) US20230285377A1 (https=)
EP (1) EP4125831A4 (https=)
JP (1) JP7838820B2 (https=)
KR (1) KR20230005168A (https=)
CN (2) CN115715189B (https=)
AU (1) AU2021241530A1 (https=)
BR (1) BR112022019041A2 (https=)
CA (1) CA3176609A1 (https=)
IL (1) IL296649A (https=)
MX (2) MX2022011813A (https=)
WO (1) WO2021195066A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139063A1 (en) * 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2020227097A1 (en) * 2019-05-03 2020-11-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
CA3169779A1 (en) 2020-02-28 2021-09-02 Andrew Mark Griffin Kcnt1 inhibitors and methods of use
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2023211854A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiazole core and methods of use
KR20250016137A (ko) * 2022-04-25 2025-02-03 프락시스 프리시젼 메디신즈, 인크. 피라졸 코어를 포함하는 kcnt1 억제제 및 사용 방법
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
EP4630399A1 (en) * 2022-12-05 2025-10-15 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
AR132248A1 (es) * 2023-03-29 2025-06-11 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos para su uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4471262B2 (ja) * 2002-03-07 2010-06-02 株式会社エス・ディー・エス バイオテック 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤
CA2663408C (en) * 2006-09-15 2011-11-01 Pfizer Inc. Substituted pyridylmethyl bicyclocarboxyamide compounds
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US10538516B2 (en) * 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂

Also Published As

Publication number Publication date
AU2021241530A1 (en) 2022-10-20
EP4125831A2 (en) 2023-02-08
KR20230005168A (ko) 2023-01-09
US20230285377A1 (en) 2023-09-14
JP2023518838A (ja) 2023-05-08
EP4125831A4 (en) 2024-05-08
MX2026000122A (es) 2026-02-03
WO2021195066A3 (en) 2021-10-21
BR112022019041A2 (pt) 2022-12-27
WO2021195066A2 (en) 2021-09-30
MX2022011813A (es) 2022-11-14
IL296649A (en) 2022-11-01
CN115715189A (zh) 2023-02-24
CA3176609A1 (en) 2021-09-30
JP7838820B2 (ja) 2026-04-01
CN121868303A (zh) 2026-04-17

Similar Documents

Publication Publication Date Title
CN115715189B (zh) Kcnt1抑制剂和使用方法
JP7824664B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
US12583849B2 (en) KCNT1 inhibitors and methods of use
EP3828174A1 (en) Pyridazinone derivative
US20240043415A1 (en) Kcnt1 inhibitors and methods of use
EP4329735B1 (en) Kcnt1 inhibitors and methods of use
US20250213558A1 (en) T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of use thereof
HK40089122A (zh) Kcnt1抑制剂和使用方法
CN108997328B (zh) 亚氨基噻二嗪二氧化物衍生物及其用途
AU2021227935B2 (en) KCNT1 inhibitors and methods of use
JP2025514140A (ja) ピラゾールコアを含むｋｃｎｔ１阻害剤及び使用方法
WO2023122152A1 (en) Kcnt1 inhibitors and methods of use
WO2024123717A1 (en) Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
WO2022231872A1 (en) Kcnt1 inhibitors and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089122

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant